<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39331603</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2767-3375</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>9</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PLOS global public health</Title><ISOAbbreviation>PLOS Glob Public Health</ISOAbbreviation></Journal><ArticleTitle>Adverse events following COVID-19 vaccination: A comprehensive analysis of spontaneous reporting data in Ghana.</ArticleTitle><Pagination><StartPage>e0003770</StartPage><MedlinePgn>e0003770</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0003770</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pgph.0003770</ELocationID><Abstract><AbstractText>Vaccines are important public health tools and formed part of the fight against the COVID-19 pandemic. Five COVID-19 vaccines were given Emergency Use Authorization in Ghana and deployed during the pandemic. Early phase trials of the vaccines were mostly not conducted in Africans. This study examines safety data during their deployment under real-life conditions in Ghana. This study analysed secondary data on COVID-19 vaccine-related adverse events following immunization (AEFI) reported to the Ghana Food and Drugs Authority (GFDA) between March 2021 and June 2022 using STATA. AEFIs were coded with their Preferred Terms using the Medical Dictionary for Regulatory Activities, version 24.0. Statistical tests examined associations between demographic characteristics, vaccine types, seriousness, and AEFI outcomes. Binary logistic regression model assessed factors associated with serious AEFIs, while the GFDA's Joint COVID-19 Vaccine Safety Review Committee provided causality assessments of serious AEFIs. Overall cumulative incidence of AEFIs was about 25 per 100,000 persons vaccinated. Across the five vaccines, majority of the AEFIs reported were not serious (98.7%) with higher incidences in those below 50 years (74.0%) and females (51.2%). The most common AEFIs recorded were headache (52.9%), pains (44.4%), pyrexia (35.1%), chills (16.7%) and injection site pain (15.6%). Relative to those 50 years and above, the odds of serious AEFI were 60% less among those aged &lt;30 years (aOR = 0.40, CI: [0.19, 0.86], p = 0.019). However, a causality assessment of the 57 serious AEFIs indicated only 8 (14%) were vaccine product-related. There was a low incidence of AEFIs following deployment of the vaccines in Ghana with a much lower incidence of serious AEFIs. Informing the public about the safety of the vaccines and potential side effects may increase trust and acceptance, decreasing hesitancy in current and future vaccination programmes.</AbstractText><CopyrightInformation>Copyright: © 2024 Asare et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Asare</LastName><ForeName>Amma Frempomaa</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0009-0006-6489-7744</Identifier><AffiliationInfo><Affiliation>Food and Drugs Authority, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabblah</LastName><ForeName>George Tsey</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Food and Drugs Authority, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buabeng</LastName><ForeName>Richard Osei</ForeName><Initials>RO</Initials><Identifier Source="ORCID">0000-0002-9500-1502</Identifier><AffiliationInfo><Affiliation>Food and Drugs Authority, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhassan</LastName><ForeName>Yakubu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, School of Public Health, University of Ghana, Legon, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asamoa-Amoakohene</LastName><ForeName>Abena</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Food and Drugs Authority, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amponsa-Achiano</LastName><ForeName>Kwame</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8145-970X</Identifier><AffiliationInfo><Affiliation>Ghana Health Service, Expanded Programme on Immunization, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammed</LastName><ForeName>Naziru Tanko</ForeName><Initials>NT</Initials><Identifier Source="ORCID">0009-0000-0278-9605</Identifier><AffiliationInfo><Affiliation>Ghana Health Service, Expanded Programme on Immunization, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darko</LastName><ForeName>Delese Mimi</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Food and Drugs Authority, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonful</LastName><ForeName>Harriet Affran</ForeName><Initials>HA</Initials><Identifier Source="ORCID">0000-0003-0069-3241</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Disease Control, School of Public Health, University of Ghana, Legon, Accra, Ghana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLOS Glob Public Health</MedlineTA><NlmUniqueID>9918283779606676</NlmUniqueID><ISSNLinking>2767-3375</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>18</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>13</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39331603</ArticleId><ArticleId IdType="pmc">PMC11432875</ArticleId><ArticleId IdType="doi">10.1371/journal.pgph.0003770</ArticleId><ArticleId IdType="pii">PGPH-D-24-01195</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaufmann SH, McElrath MJ, Lewis DJ, Del Giudice G. Challenges and responses in human vaccine development. Current opinion in immunology. 2014. Jun 1;28:18–26. doi: 10.1016/j.coi.2014.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2014.01.009</ArticleId><ArticleId IdType="pubmed">24561742</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A, Khillan R, Mishra Y, Khurana S. The safety profile of COVID-19 vaccinations in the United States. American journal of infection control. 2022. Jan 1;50(1):15–9. doi: 10.1016/j.ajic.2021.10.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2021.10.015</ArticleId><ArticleId IdType="pmc">PMC8539830</ArticleId><ArticleId IdType="pubmed">34699960</ArticleId></ArticleIdList></Reference><Reference><Citation>Breugelmans J, Lewis RF, Agbenu E, Veit O, Jackson D, Domingo C, et al.. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine. 2013. Apr 3;31(14):1819–29. doi: 10.1016/j.vaccine.2013.01.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.01.054</ArticleId><ArticleId IdType="pubmed">23395587</ArticleId></ArticleIdList></Reference><Reference><Citation>Tozzi AE, Asturias EJ, Balakrishnan MR, Halsey NA, Law B, Zuber PL. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine. 2013. Oct 17;31(44):5041–6. doi: 10.1016/j.vaccine.2013.08.087</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.08.087</ArticleId><ArticleId IdType="pubmed">24021304</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatmal MM, Al-Hatamleh MA, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al.. Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines. 2021. May 26;9(6):556. doi: 10.3390/vaccines9060556</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9060556</ArticleId><ArticleId IdType="pmc">PMC8229440</ArticleId><ArticleId IdType="pubmed">34073382</ArticleId></ArticleIdList></Reference><Reference><Citation>Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. Journal of Clinical Medicine. 2021. Apr 1;10(7):1428. doi: 10.3390/jcm10071428</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10071428</ArticleId><ArticleId IdType="pmc">PMC8037149</ArticleId><ArticleId IdType="pubmed">33916020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how’s and what’s of vaccine reactogenicity. npj Vaccines. 2019. Sep 24;4(1):1–1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760227</ArticleId><ArticleId IdType="pubmed">31583123</ArticleId></ArticleIdList></Reference><Reference><Citation>Defendi HG, da Silva Madeira L, Borschiver S. Analysis of the COVID-19 vaccine development process: an exploratory study of accelerating factors and innovative environments. Journal of Pharmaceutical Innovation. 2021. Feb 2:1–7. doi: 10.1007/s12247-021-09535-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12247-021-09535-8</ArticleId><ArticleId IdType="pmc">PMC7851325</ArticleId><ArticleId IdType="pubmed">33552310</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020. Oct;586(7830):516–27. doi: 10.1038/s41586-020-2798-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2798-3</ArticleId><ArticleId IdType="pubmed">32967006</ArticleId></ArticleIdList></Reference><Reference><Citation>Petousis-Harris H. Assessing the safety of COVID-19 vaccines: a primer. Drug safety. 2020. Dec;43(12):1205–10. doi: 10.1007/s40264-020-01002-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-01002-6</ArticleId><ArticleId IdType="pmc">PMC7526515</ArticleId><ArticleId IdType="pubmed">32997318</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al.. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC medicine. 2021. Dec;19:1–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8315897</ArticleId><ArticleId IdType="pubmed">34315454</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd RH, Cvejic E, Bonner C, Pickles K, McCaffery KJ, Ayre J, et al.. Willingness to vaccinate against COVID-19 in Australia. The Lancet Infectious Diseases. 2021. Mar 1;21(3):318–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326391</ArticleId><ArticleId IdType="pubmed">32619436</ArticleId></ArticleIdList></Reference><Reference><Citation>Acheampong T, Akorsikumah EA, Osae-Kwapong J, Khalid M, Appiah A, Amuasi JH. Examining vaccine hesitancy in Sub-Saharan Africa: a survey of the knowledge and attitudes among adults to receive COVID-19 vaccines in Ghana. Vaccines. 2021. Jul 22;9(8):814. doi: 10.3390/vaccines9080814</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9080814</ArticleId><ArticleId IdType="pmc">PMC8402404</ArticleId><ArticleId IdType="pubmed">34451939</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter SM, Li D, Trentino K, Nissen L, Lee K, Orlemann K, et al.. Safety of four COVID-19 vaccines across primary doses 1, 2, 3 and booster: a prospective cohort study of Australian community pharmacy vaccinations. Vaccines. 2022. Nov 25;10(12):2017. doi: 10.3390/vaccines10122017</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10122017</ArticleId><ArticleId IdType="pmc">PMC9786585</ArticleId><ArticleId IdType="pubmed">36560426</ArticleId></ArticleIdList></Reference><Reference><Citation>Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews. 2021. Sep 1;15(5):102207. doi: 10.1016/j.dsx.2021.102207</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.102207</ArticleId><ArticleId IdType="pmc">PMC8274281</ArticleId><ArticleId IdType="pubmed">34280733</ArticleId></ArticleIdList></Reference><Reference><Citation>Zare H, Rezapour H, Mahmoodzadeh S, Fereidouni M. Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran. International immunopharmacology. 2021. Dec 1;101:108351. doi: 10.1016/j.intimp.2021.108351</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108351</ArticleId><ArticleId IdType="pmc">PMC8577998</ArticleId><ArticleId IdType="pubmed">34801416</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum HG, Hadler SC, Moulia D, Shimabukuro TT, Su JR, Tepper NK, et al.. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson &amp; Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices—United States, July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1094–1099. doi: 10.15585/mmwr.mm7032e4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7032e4</ArticleId><ArticleId IdType="pmc">PMC8360272</ArticleId><ArticleId IdType="pubmed">34383735</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, et al.. Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination. Pediatrics. 2021. Sep 1;148(3). doi: 10.1542/peds.2021-052478</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2021-052478</ArticleId><ArticleId IdType="pubmed">34088762</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al.. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. Jama. 2022. Jan 25;327(4):331–40. doi: 10.1001/jama.2021.24110</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.24110</ArticleId><ArticleId IdType="pmc">PMC8790664</ArticleId><ArticleId IdType="pubmed">35076665</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavda VP, Bezbaruah R, Valu D, Patel B, Kumar A, Prasad S, et al.. Adenoviral vector-based vaccine platform for COVID-19: Current status. Vaccines. 2023. Feb 13;11(2):432. doi: 10.3390/vaccines11020432</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11020432</ArticleId><ArticleId IdType="pmc">PMC9965371</ArticleId><ArticleId IdType="pubmed">36851309</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobaiqy M, Elkout H, MacLure K. Analysis of thrombotic adverse reactions of COVID-19 AstraZeneca vaccine reported to EudraVigilance database. Vaccines. 2021. Apr 16;9(4):393. doi: 10.3390/vaccines9040393</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9040393</ArticleId><ArticleId IdType="pmc">PMC8074142</ArticleId><ArticleId IdType="pubmed">33923530</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver SE. Use of the Janssen (Johnson &amp; Johnson) COVID-19 vaccine: updated interim recommendations from the advisory committee on immunization practices—United States, December 2021. MMWR. Morbidity and Mortality Weekly Report. 2022;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8774160</ArticleId><ArticleId IdType="pubmed">35051137</ArticleId></ArticleIdList></Reference><Reference><Citation>Shay DK. Safety monitoring of the Janssen (Johnson &amp; Johnson) COVID-19 vaccine—United States, March–April 2021. MMWR. Morbidity and mortality weekly report. 2021;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9368748</ArticleId><ArticleId IdType="pubmed">33956784</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drugs Authority. Emergency Use Authorization of Medical Products [Internet]. Food and Drugs Authority. [cited 2024 Jul 19]. https://fdaghana.gov.gh/img/convid/FDA_EMERGENCY%20USE%20AUTHORIZATION.pdf</Citation></Reference><Reference><Citation>Food and Drugs Authority. COVID-19 Vaccines Granted Emergency Use Authorization (EUA) by the Ghana Food and Drugs Authority (FDA) [Internet]. Food and Drugs Authority. [cited 2024 Jul 19]. https://fdaghana.gov.gh/img/convid/LIST%20OF%20COVID-19%20VACCINES%20GRANTED%20EUA%20BY%20GHANA%20FDA1.pdf</Citation></Reference><Reference><Citation>Ghana Health Service. COVID-19 Updates [Internet]. Ghana Health Service; [cited 2022 Jun 30]. https://ghs.gov.gh/covid19/archive.php</Citation></Reference><Reference><Citation>World Health Organization. Immunization safety surveillance: guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. WHO Regional Office for the Western Pacific; 1999.</Citation></Reference><Reference><Citation>Bong CL, Brasher C, Chikumba E, McDougall R, Mellin-Olsen J, Enright A. The COVID-19 pandemic: effects on low-and middle-income countries. Anesthesia &amp; Analgesia. 2020. Jul 1;131(1):86–92. doi: 10.1213/ANE.0000000000004846</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000004846</ArticleId><ArticleId IdType="pmc">PMC7173081</ArticleId><ArticleId IdType="pubmed">32243287</ArticleId></ArticleIdList></Reference><Reference><Citation>Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi pharmaceutical journal. 2014. Apr 1;22(2):83–94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3950535</ArticleId><ArticleId IdType="pubmed">24648818</ArticleId></ArticleIdList></Reference><Reference><Citation>Basavaraja CK, Sebastian J, Ravi MD, John SB. Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India. Therapeutic Advances in Vaccines and Immunotherapy. 2021. Nov;9:25151355211055833. doi: 10.1177/25151355211055833</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/25151355211055833</ArticleId><ArticleId IdType="pmc">PMC8611289</ArticleId><ArticleId IdType="pubmed">34841193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots.</Citation><ArticleIdList><ArticleId IdType="pubmed">33707182</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drugs Authority. [Internet]. Food and Drugs Authority. [cited 2023 Oct 10]. https://www.fdaghana.gov.gh/general-publication.php</Citation></Reference><Reference><Citation>World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification second edition 2019 update.</Citation></Reference><Reference><Citation>International Conference on Harmonization. Introductory Guide MedDRA Version 24.0. 2021 [Internet]. [cited 2024 Jan 11]. https://www.meddra.org/how-to-use/support-documentation/english</Citation></Reference><Reference><Citation>Kant A, Jansen J, van Balveren L, van Hunsel F. Description of frequencies of reported adverse events following immunization among four different COVID-19 vaccine brands. Drug safety. 2022. Apr;45(4):319–31. doi: 10.1007/s40264-022-01151-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-022-01151-w</ArticleId><ArticleId IdType="pmc">PMC8936041</ArticleId><ArticleId IdType="pubmed">35314943</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan SS, Rashid A, Osama S, Mustafa ZU, Merchant HA. COVID-19 vaccine safety and adverse event analysis from Pakistan. Clinical Immunology Communications. 2022. Dec 1;2:91–7. doi: 10.1016/j.clicom.2022.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clicom.2022.05.003</ArticleId><ArticleId IdType="pmc">PMC9107183</ArticleId><ArticleId IdType="pubmed">38013971</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al.. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2020. Aug 15;396(10249):479–88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836858</ArticleId><ArticleId IdType="pubmed">32702299</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagotto V, Ferloni A, Soriano MM, Díaz M, Golde MB, González MI, et al.. Active surveillance of the SPUTNIK V vaccine in health workers. MedRxiv. 2021. Feb 5:2021–02.</Citation></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b.</Citation></Reference><Reference><Citation>Zou C, Xue X, Qian J. Characteristics and comparison of adverse events of coronavirus disease 2019 vaccines reported to the United States vaccine adverse event reporting system between 14 December 2020 and 8 October 2021. Frontiers in Medicine. 2022. Apr 5;9:826327. doi: 10.3389/fmed.2022.826327</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.826327</ArticleId><ArticleId IdType="pmc">PMC9016134</ArticleId><ArticleId IdType="pubmed">35449806</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayadevan R, Shenoy R, TS A. Survey of symptoms following COVID-19 vaccination in India. Medrxiv. 2021. Feb 12:2021–02.2 mRNA Covid-19 vaccine. New England journal of medicine. 2020 Dec 31;383(27):2603–15.</Citation></Reference><Reference><Citation>Mohammed RA, Garout RM, Wahid S, Ayub F, ZinAlddin LM, Sultan I, et al.. A survey on the side effects of Pfizer/BioNTech COVID-19 vaccine among vaccinated adults in Saudi Arabia. Cureus. 2021. Nov 3;13(11). doi: 10.7759/cureus.19222</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.19222</ArticleId><ArticleId IdType="pmc">PMC8640570</ArticleId><ArticleId IdType="pubmed">34873547</ArticleId></ArticleIdList></Reference><Reference><Citation>Odeigah LO, Mutalub YB, Agede OA, Obalowu IA, Aiyetoro S, Jimoh GA. Adverse events following COVID-19 vaccination in Kwara State, North-central Nigeria. PLOS Global Public Health. 2022. Aug 15;2(8):e0000835. doi: 10.1371/journal.pgph.0000835</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgph.0000835</ArticleId><ArticleId IdType="pmc">PMC10021916</ArticleId><ArticleId IdType="pubmed">36962774</ArticleId></ArticleIdList></Reference><Reference><Citation>Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al.. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020. Aug 15;396(10249):467–78. doi: 10.1016/S0140-6736(20)31604-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31604-4</ArticleId><ArticleId IdType="pmc">PMC7445431</ArticleId><ArticleId IdType="pubmed">32702298</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al.. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet. 2020. Dec 19;396(10267):1979–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674972</ArticleId><ArticleId IdType="pubmed">33220855</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur U, Ojha B, Pathak BK, Singh A, Giri KR, Singh A, et al.. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers-first results from India. EClinicalMedicine. 2021. Aug 1;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8413251</ArticleId><ArticleId IdType="pubmed">34505032</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al.. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New England Journal of Medicine. 2020. Dec 17;383(25):2427–38. doi: 10.1056/NEJMoa2028436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028436</ArticleId><ArticleId IdType="pmc">PMC7556339</ArticleId><ArticleId IdType="pubmed">32991794</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England journal of medicine. 2021. Feb 4;384(5):403–16. doi: 10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al.. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases. 2021. Jul 1;21(7):939–49. doi: 10.1016/S1473-3099(21)00224-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00224-3</ArticleId><ArticleId IdType="pmc">PMC8078878</ArticleId><ArticleId IdType="pubmed">33930320</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, et al.. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. Life. 2021. Mar 17;11(3):249. doi: 10.3390/life11030249</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life11030249</ArticleId><ArticleId IdType="pmc">PMC8002738</ArticleId><ArticleId IdType="pubmed">33803014</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohseni Afshar Z, Babazadeh A, Janbakhsh A, Mansouri F, Sio TT, Sullman MJ, et al.. Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities. Reviews in medical virology. 2022. May;32(3):e2309. doi: 10.1002/rmv.2309</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2309</ArticleId><ArticleId IdType="pmc">PMC8646697</ArticleId><ArticleId IdType="pubmed">34677889</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. COVID-19 Vaccine AstraZeneca, COVID-19 Vaccine (ChAdOx1-S [recombinant]) [Internet]. [cited 2024 Aug 15]. https://extranet.who.int/prequal/sites/default/files/document_files/smpc-azd1222_Jan2023.pdf</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>